Neurology

A preview of what's genuinely new. Sign up for your full, always-current stack.

ResearchSource: NeurologyNov 10, 2026

Intensive BP Lowering Benefits Deep but Not Lobar Hemorrhage

A pooled individual patient-level analysis of five randomized trials (INTERACT1-4 and ATACH-II), totaling 11,288 patients with acute intracerebral hemorrhage, examined whether the benefit of early intensive blood pressure lowering varies by hematoma location. The analysis reported that treatment effect on death or disability at 90 days or 6 months differed significantly by location, with a clear benefit observed only in deep hemisphere ICH (adjusted odds ratio 0.81) and no clear benefit shown for lobar or infratentorial hemorrhage.

Relevant to:NeurologyPatients presenting with acute intracerebral hemorrhage, particularly where hematoma location (deep, lobar, or infratentorial) is being considered in blood pressure management decisions.

View source

ResearchSource: JAMA NeurologyOct 5, 2026

Earlier Blood Biomarker Disclosure Boosts Diagnostic Certainty in Memory Clinic

A randomized trial at a Spanish memory clinic tested earlier versus delayed disclosure of plasma p-tau217 and NfL results in 220 outpatients with subjective cognitive decline, MCI, or mild dementia. The trial reported that earlier disclosure increased very high-confidence etiologic diagnoses (50.0% vs 4.6% at 3 months), was associated with more frequent initiation of symptomatic AD treatment, fewer follow-up neuropsychological reassessments, and more discharges to primary care, without worsening emotional outcomes.

Relevant to:NeurologyPatients being evaluated in memory clinics for subjective cognitive decline, mild cognitive impairment, or mild dementia without an established etiologic diagnosis.

View source

ResearchSource: NeurologyOct 27, 2026

Iatrogenic cerebral amyloid angiopathy linked to high recurrent hemorrhage risk

A multinational case series of 82 patients with iatrogenic cerebral amyloid angiopathy (iCAA) found a symptomatic intracerebral hemorrhage (ICH) rate of 19.2 per 100 patient-years after first presentation, the study reports. Patients who initially presented with ICH had a higher recurrence rate (24.6 per 100 patient-years) than those with other presentations, and those exposed via spinal surgery had a lower ICH rate than those exposed via brain surgery or embolization, according to the authors. Despite frequent hemorrhage, mortality was low (7.3%), while cognitive impairment was recorded in just over half of patients at last follow-up.

Relevant to:NeurologyPatients diagnosed with iatrogenic cerebral amyloid angiopathy following prior neurosurgical or embolization procedures.

View source

ResearchSource: NeurologyOct 27, 2026

Study identifies clinical risk factors for chemotherapy-induced nerve toxicity

A cross-sectional multisite study of 901 individuals treated with neurotoxic cancer agents (taxanes, platinum, vinca alkaloids, bortezomib, thalidomide) assessed chemotherapy-induced peripheral neurotoxicity (CIPN) using clinical grading, neurologic evaluation, and patient-reported outcomes. The study reported that 37% had moderate-to-severe CIPN and 31% required dose modification due to CIPN, with female sex associated with dose-limiting CIPN, and older age, diabetes, higher BMI, and prior neurotoxic treatment associated with post-treatment and severe CIPN across assessment tools. The authors stated these are clinical variables available at treatment initiation that suggest increasing susceptibility to developing CIPN.

Relevant to:NeurologyPatients receiving neurotoxic chemotherapy agents such as taxanes, platinum compounds, vinca alkaloids, bortezomib, or thalidomide, particularly those with diabetes, higher BMI, older age, or prior neurotoxic treatment.

View source

ResearchSource: NeurologyOct 27, 2026

Cervical cord atrophy in MS exceeds normal age-related decline

A cross-sectional, multicenter study of 480 healthy controls and 1,295 patients with multiple sclerosis used MRI to model upper cervical cord area across the lifespan and compare patients with MS to expected age-related trajectories. The study reported that patients with MS showed cord area reductions beyond normal aging starting around age 30, most pronounced in the fifth and sixth decades, with this disease-specific atrophy occurring independent of sex and correlating with higher disability and other structural MRI changes. Differences by age at disease onset were largely explained by disease duration rather than onset age itself, according to the study.

Relevant to:NeurologyPatients with multiple sclerosis, particularly those being evaluated with spinal cord MRI for disability and disease progression monitoring.

View source

Get your full stack

Neurology

Intensive BP Lowering Benefits Deep but Not Lobar Hemorrhage

Earlier Blood Biomarker Disclosure Boosts Diagnostic Certainty in Memory Clinic

Iatrogenic cerebral amyloid angiopathy linked to high recurrent hemorrhage risk

Study identifies clinical risk factors for chemotherapy-induced nerve toxicity

Cervical cord atrophy in MS exceeds normal age-related decline

Earlier neurology updates

Neurology

Intensive BP Lowering Benefits Deep but Not Lobar Hemorrhage

Earlier Blood Biomarker Disclosure Boosts Diagnostic Certainty in Memory Clinic

Iatrogenic cerebral amyloid angiopathy linked to high recurrent hemorrhage risk

Study identifies clinical risk factors for chemotherapy-induced nerve toxicity

Cervical cord atrophy in MS exceeds normal age-related decline

Earlier neurology updates

Neurology

Recent updates

Earlier neurology updates

Neurology

Recent updates

Earlier neurology updates